Compare Ginkgo Bioworks Holdings Inc (DNA) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Jones Lang LaSalle Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B). The key difference: Jones Lang LaSalle Inc is far larger — about 18.3× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Jones Lang LaSalle Inc for 71 Days on average.
| DNA | JLL | |
|---|---|---|
Market Cap | $763.64M | $13.95B |
Volume | 3,204,177 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $15.83 | $392.79 |
52-Week Low | $5.48 | $280.16 |
Typical Hold Time | 7 Days | 71 Days |
Enterprise Value | $865.59M | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
JLL trades at $303.14, up 2.18% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $26.12B in 2025 and improving profit margins. Analyst consensus remains bullish with a $450.50 price target, though technical indicators suggest near-term caution.
JLL presents a compelling value opportunity with attractive valuation ratios (P/E 14.54, P/S 0.53) and consistent earnings outperformance. Key risks include real estate market cyclicality and competitive pressures, but strong institutional support and strategic acquisitions support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
